Belkin supercharges into CES 2024 with powerful new product lineup
Belkin, a leading consumer electronics brand for 40 years, today introduced four new products across its mobile power and connectivity portfolios, underscoring Belkin innovation, design excellence, dedication to quality, and commitment to building products more responsibly. Belkin is showcasing its newly announced products at CES Unveiled Las Vegas – the official media event of CES 2024.
This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20240107725407/en/
Belkin supercharges into CES 2024 with powerful new product lineup (Photo: Business Wire)
Charging in a snap with Qi2
BoostCharge Pro 3-in-1 Magnetic Stand
Leveraging the new Qi2 standard, this powerful 3-in-1 wireless charger offers perfect alignment and reliable charging for Qi2-enabled devices at 15W, fast charging for Apple Watch Series 7 and later, and optimal charging for wireless earbuds. Built to include an adjustable hinge, users can effortlessly adjust the angle of the phone for optimal viewing while watching videos, reading articles or video chatting. It is made with a minimum 75% post-consumer recycled (PCR) materials.
$149.99 USD
Coming March 2024 to select markets worldwide
BoostCharge Pro Magnetic Power Bank
The Qi2 magnetic power bank delivers up to 15W of power for Qi2-enabled devices on-the-go, without the hassle of cables. It is engineered with an integrated kickstand for propping the phone up while streaming, reading, or chatting, and works with magnetic and MagSafe cases up to 3mm thick. “Power pass-through” allows for charging the power bank and Qi2 device in one simple action via USB-C port. Offered in 5K, 8K and 10K options, consumers can choose the best power bank for their charging needs. Internal housing (excluding cable) of this product is made with a minimum 72% PCR materials.
$59.99, $79.99, $99.99 USD
Coming March 2024 to select markets worldwide
Power-packed and compact with GaN
BoostCharge Pro 4-Port USB-C GaN Charger 200W
The new 4-Port USB-C GaN Wall Charger packs an impressive 200W of power for fast charging up to 4 devices at the same time. It supports high powered laptops and gaming laptops and is engineered with GaN technology and Programmable Power Supply (PPS) to provide efficient power output and smart power allocation, giving connected devices a safe and optimal charge. The 4-Port USB-C GaN Wall Charger declutters the workspace while charging laptops, tablets, phones, smart watches and earbuds simultaneously – no extra power bricks needed. It is compact and power-packed, measured at 92mm x 118.5mm x 35.5mm, and 650g/1.32lbs. The housing (excluding power cord) of this product is made with a minimum 72% PCR materials.
$129.99 USD
Coming March 2024 to belkin.com and select markets worldwide
6-in-1 Core GaN Dock
Belkin is innovating its docks category with the use of GaN to deliver smaller, more efficient, more responsible workspace solutions. Approximately 50 percent smaller1 than other 6-in-1 solutions and highly spec'd to support all essential needs, the Core GaN Dock features 1x HDMI port for high-definition display resolutions up to 4K, 2x USB-A ports for legacy devices, 2x USB-C ports (1 with 96W power delivery), and 1 gigabit ethernet port for secure and reliable Internet connection.
$139.99 USD
Available to order now on belkin.com
Coming soon to select retailers worldwide
Built more responsibly
In line with the company’s commitment to find more responsible ways to build products, Belkin’s newly announced BoostCharge solutions are made with a minimum of 72% PCR materials and sold in plastic-free packaging. One year since Belkin announced its transition to PCR, it has transitioned over 200 products to incorporate PCR, and has replaced 64 metric tons of virgin plastic with PCR materials. Belkin remains committed to its goal of 100% carbon neutrality in its offices and operations (scope 1 & 2 emissions) by 2025 while tackling product level emissions (scope 3).
Media kit is available for download HERE.
About Belkin
Belkin is a California-based accessories leader delivering award-winning power, protection, productivity, connectivity, and audio products over the last 40 years. Designed and engineered in Southern California and sold in more than 100 countries around the world, Belkin has maintained its steadfast focus on research and development, community, education, sustainability and most importantly, the people it serves. From the humble beginnings of a garage in 1980s Southern California to a diverse, global technology company today, we remain forever inspired by the planet we live on, and the connection between people and technology.
1 Based on internal tests against competing non-GaN solutions with power supply unit. Dimensions: 80 x 80 x 48mm; surface area: 6,400mm
To view this piece of content from cts.businesswire.com, please give your consent at the top of this page.
View source version on businesswire.com: https://www.businesswire.com/news/home/20240107725407/en/
Contact information
For Media Inquiries:
Jen Wei
VP of Global Communications and Corporate Development
Comms@belkin.com
About Business Wire
For more than 50 years, Business Wire has been the global leader in press release distribution and regulatory disclosure.
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
New Data From Landmark HELIOS-B Phase 3 Study Presented at ESC Congress 2025 Demonstrate Vutrisiran’s Long-Term Cardiovascular Benefit in ATTR-CM31.8.2025 12:15:00 EEST | Press release
Alnylam Pharmaceuticals, Inc. (Nasdaq: ALNY), the leading RNAi therapeutics company, today announced results of new analyses from the HELIOS-B Phase 3 study of AMVUTTRA® (vutrisiran), an RNAi therapeutic approved for the treatment of the cardiomyopathy of wild-type or hereditary transthyretin-mediated amyloidosis (ATTR-CM) in adults. Data from the 12-month follow-up of the ongoing open-label extension (OLE) period of HELIOS-B were presented during an oral session at the European Society of Cardiology (ESC) Congress 2025 held in Madrid, Spain. These data reflect outcomes of treatment through up to 48 months, including the initial double-blind period of 33-36 months, and highlight the ongoing clinical benefit of vutrisiran, which causes rapid knockdown of the disease-causing transthyretin (TTR) protein, including a 37% risk reduction in the composite endpoint of all-cause mortality (ACM) or first cardiovascular (CV) event in the overall population (p<0.001) and a 42% risk reduction in th
WETEX Opens Broad Investment Horizons for International Companies31.8.2025 09:30:00 EEST | Press release
Under the directives of HH Sheikh Mohammed bin Rashid Al Maktoum, Vice President and Prime Minister of the UAE and Ruler of Dubai, and the patronage of HH Sheikh Ahmed bin Saeed Al Maktoum, Chairman of the Dubai Supreme Council of Energy, Dubai Electricity and Water Authority (DEWA) will organise the 27th edition of the Water, Energy, Technology and Environment Exhibition (WETEX) from 30 September to 2 October 2025 at the Dubai World Trade Centre. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20250830023664/en/ WETEX opens broad investment horizons for international companies (Photo: AETOSWire) WETEX embodies the UAE's pioneering position in clean and renewable energy and sustainability. It also supports Dubai's ambitious vision of a sustainable economy. The exhibition covers multiple areas including water, energy, smart cities, green mobility, artificial intelligence and digital transformation. “WETEX reflects the UAE's unwa
Daiichi Sankyo Announces the Initiation of the Development of Oral Triple Combination Lipid-Lowering Tablets to Support the Management of LDL-C30.8.2025 19:00:00 EEST | Press release
Daiichi Sankyo Europe is pleased to announce the initiation of the development of new oral triple combination tablets in Europe of bempedoic acid, ezetimibe, and different doses of a statin (atorvastatin or rosuvastatin), with the potential to lower low-density lipoprotein cholesterol (LDL-C) levels.9 It is well known that combination therapies reduce the pill burden for patients, potentially enhancing treatment adherence and facilitating treatment with a goal of improving cardiovascular outcomes.9,10 “As bempedoic acid and ezetimibe are already approved as a single-dose therapy, the development of an oral triple combination tablet with different doses of a statin, can make it easier for physicians to tailor treatment to the individual needs of each patient,” says Dr. Stefan Seyfried, Vice President and Head Medical Affairs Specialty Medicines, Daiichi Sankyo Europe. “This approach exemplifies our dedication to our motto: ‘we care for every heartbeat’.” “The management of dyslipidaemia
Alnylam to Advance Zilebesiran into Global Phase 3 Cardiovascular Outcomes Trial30.8.2025 17:30:00 EEST | Press release
Alnylam Pharmaceuticals, Inc. (Nasdaq: ALNY), the leading RNAi therapeutics company, today announced plans to initiate a Phase 3 cardiovascular outcomes trial (CVOT) to evaluate the potential of zilebesiran to reduce the risk of major adverse cardiovascular events. This decision is informed by results from the comprehensive KARDIA Phase 2 program, including KARDIA-3 results presented today as a late-breaking abstract at the European Society of Cardiology (ESC) Congress in Madrid, Spain. Zilebesiran is an investigational subcutaneously administered RNAi therapeutic which, in the KARDIA Phase 2 program, has shown reductions in blood pressure by targeting liver-expressed angiotensinogen (AGT), the most upstream precursor in the Renin-Angiotensin-Aldosterone System (RAAS), which plays a key role in blood pressure regulation and impacts cardiovascular and renal health. KARDIA-3, the third Phase 2 study in the KARDIA program, evaluated the efficacy and safety of zilebesiran in patients with
BeOne Medicines Announces Positive Topline Results for Sonrotoclax in Relapsed or Refractory Mantle Cell Lymphoma (MCL)29.8.2025 13:00:00 EEST | Press release
BeOne Medicines Ltd. (Nasdaq: ONC; HKEX: 06160; SSE: 688235), a global oncology company, today announced positive topline results from a Phase 1/2 study (BGB-11417-201) of sonrotoclax, a next-generation and potentially best-in-class investigational BCL2 inhibitor, in adult patients with relapsed/refractory (R/R) mantle cell lymphoma (MCL), following treatment with a Bruton’s tyrosine kinase inhibitor (BTKi) and anti-CD20 therapy. BeOne plans to present the full data at an upcoming medical meeting. “For people with relapsed or refractory mantle cell lymphoma, the disease is aggressive, the treatment landscape fragmented, and the outcomes unacceptably poor. These topline results for sonrotoclax underscore its potential to deliver meaningful and durable responses and offer the first BCL2 inhibitor for patients with R/R MCL, if approved,” said Lai Wang, PhD, Global Head of R&D, BeOne Medicines. “These data add to the remarkable progress we’ve seen over the past five years in treating B-cel
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom